Regulatory Affairs and Adaptive Designs Greg Enas, PhD, RAC Director, Endocrinology/Metabolism US Regulatory Affairs Eli Lilly and Company.

Slides:



Advertisements
Similar presentations
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Advertisements

Drugs vs. Devices Jeng Mah & Gosford A Sawyerr Sept 16, 2005.
Agency for Healthcare Research and Quality (AHRQ)
Study Objectives and Questions for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Randomized Controlled Trial
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Susan Boynton, VP, Global Regulatory Affairs, Shire
Comparator Selection in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Breakout Session 4: Personalized Medicine and Subgroup Selection Christopher Jennison, University of Bath Robert A. Beckman, Daiichi Sankyo Pharmaceutical.
Data Monitoring Models and Adaptive Designs: Some Regulatory Experiences Sue-Jane Wang, Ph.D. Associate Director for Adaptive Design and Pharmacogenomics,
The Statisticians Role in Pharmaceutical Development
Federal Institute for Drugs and Medical Devices | The Farm is a Federal Institute within the portfolio of the Federal Ministry of Health (Germany) How.
Mitochondrial Manipulation Technologies: Preclinical Considerations
ODAC May 3, Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.
Estimation and Reporting of Heterogeneity of Treatment Effects in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare.
Elements of a clinical trial research protocol
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Clinical Trials Hanyan Yang
Special Topics in IND Regulation
Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.
Adaptive Designs for Clinical Trials
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
Analysis of Clinical Trials with Multiple Outcomes Changchun Xie, PhD Assistant Professor of Biostatistics Division of Biostatistics and Bioinformatics.
Adaptive designs as enabler for personalized medicine
Stefan Franzén Introduction to clinical trials.
Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School
Aligning Trial Design and Key Processes in Phase III Event Driven Trials: Protocol (via a Special Protocol Assessment), Data Monitoring Committee Charter.
Delivering Robust Outcomes from Multinational Clinical Trials: Principles and Strategies Andreas Sashegyi, PhD Eli Lilly and Company.
A Benefit-Risk Model to Facilitate DMC-Sponsor Communication and Decision Making Andreas Sashegyi PhD ELI LILLY AND COMPANY 1.
The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.
HOW TO WRITE RESEARCH PROPOSAL BY DR. NIK MAHERAN NIK MUHAMMAD.
CHP400: Community Health Program - lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Present: Disease Past: Exposure Cross - section.
Integrated Risk Management Charles Yoe, PhD Institute for Water Resources 2009.
An agency of the European Union Presented by: Paolo Tomasi Data Safety Monitoring Boards / Data Monitoring Committees in paediatric studies Paolo Tomasi,
Evidence-Based Medicine: What does it really mean? Sports Medicine Rounds November 7, 2007.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
Development and Approval of Drugs and Devices EPI260 Lecture 6: Late Phase Clinical Trials April 28, 2011 Richard Chin, M.D.
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health (BMG) The use of.
Using Predictive Classifiers in the Design of Phase III Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
August 20, 2003FDA Antiviral Drugs Advisory Committee Meeting 1 Statistical Considerations for Topical Microbicide Phase 2 and 3 Trial Designs: A Regulatory.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
EBM --- Journal Reading Presenter :呂宥達 Date : 2005/10/27.
INTRODUCTION TO CLINICAL RESEARCH Introduction to Statistical Inference Karen Bandeen-Roche, Ph.D. July 12, 2010.
Biotechnology Industry Organization (BIO) Risk Management Public Workshop Day 1 - April 9, 2003 Risk Assessment in Drug and Biological Development Joanna.
Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.
Gwendolyn Ryals, Look at Me Artwork from The Creative Center Janey Shin, Director, Real World Evidence Government Affairs and Market Access CADTH Symposium.
Adaptive trial designs in HIV vaccine clinical trials Morenike Ukpong Obafemi Awolowo University Ile-Ife, Nigeria.
Regulatory and Reimbursement Harmonization An Industry Perspective Adrian Griffin | April 2016.
The Stages of a Clinical Trial
Patient Focused Drug Development An FDA Perspective
CLINICAL PROTOCOL DEVELOPMENT
FDA’s IDE Decisions and Communications
Community Participation in Research
Prof. Dr. Basavaraj K. Nanjwade
8. Causality assessment:
Statistical Approaches to Support Device Innovation- FDA View
Supplementary Table 1. PRISMA checklist
Deputy Director, Division of Biostatistics No Conflict of Interest
Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.
Strategies for Implementing Flexible Clinical Trials Jerald S. Schindler, Dr.P.H. Cytel Pharmaceutical Research Services 2006 FDA/Industry Statistics Workshop.
Regulatory perspective
Is a Clinical Trial Right for Me?
Aiying Chen, Scott Patterson, Fabrice Bailleux and Ehab Bassily
Use of Real-World Data in Clinical Drug Development
Issues in Hypothesis Testing in the Context of Extrapolation
Development Plans: Study Design and Dose Selection
Optimal Basket Designs for Efficacy Screening with Cherry-Picking
Regulatory Perspective of the Use of EHRs in RCTs
David Manner JSM Presentation July 29, 2019
Assessing Similarity to Support Pediatric Extrapolation
Presentation transcript:

Regulatory Affairs and Adaptive Designs Greg Enas, PhD, RAC Director, Endocrinology/Metabolism US Regulatory Affairs Eli Lilly and Company

Key Messages Adaptive designs open doors to realize the promise of translational medicine advocated by regulators At each stage of drug development, regulators use a “lens” for their review of adaptive design proposals, protocols, and study results Sponsors must not be shy about approaching regulatory agencies with adaptive design proposals, especially Phase 1 and 2. Sponsors should thoughtfully consider adaptive design proposals as part of Phase 3, especially in the context of larger confirmatory program.

Outline What’s important to regulators When and with what should sponsors communicate with regulators New horizons for adaptive designs in the regulatory context Note: US FDA administrative focus but regulatory science principles generalizeable

What’s Important to Regulators? Probability that the wrong dose or the wrong drug is administered to the wrong patient at the wrong time must be known to be acceptably low At each stage of drug development, regulators use a “lens” for their review –Meaning of any claims or conclusions made –Relationship between claims and evidence –Quality of the evidence –Totality of the evidence (e.g. “substantial”)

Meaning of Claims Claims must be stated in terms of clearly defined hypotheses that convincingly dominate other plausible hypotheses Regulatory scientific paradigm for confirmation of claims is constructed via hypothesis testing framework –H0: This agent should not be approved H1: This agent should be approved Regulators adopted frequentist approach for drugs and biopharmaceuticals; Bayesian approach also acceptable for device approval

Relationship between Claims and Evidence Clinical development program design –Individual study designs Hypotheses to test and relationships to model Sample size, Type 1 and 2 error limits, effect size, confidence interval width Primary and secondary endpoints Patient populations (inclusion, exclusion criteria) Post accrual adaptations within and between patients (concomitant medications, rescue Rx, etc)

Relationship between Claims and Evidence (continued) Designed to progressively discharge uncertainty related to desired claims –Start smaller / end bigger Enriched proof of concept, then generalize –Start bigger / end smaller Explore heterogeneity, then target –Biomarker and diagnostic test qualification –Overall and subgroup exploration / testing –Program-wise error rates (across studies)

Quality of the Evidence Randomization and Blinding Minimize unplanned changes post randomization Certify that planned post randomization changes do not bias inferences Transparency – tell regulators what you plan to do, then do what you say you will do and inform them that you did (or did not) do it the way you planned

Totality of the Evidence Patient safety first ! Benefits (B) must outweigh risks (R) –If B<R then minimize exposure –If B>R then maximize exposure (or must B>>R ?) –If B = R then assume B<R Total patient exposures needed to estimate R dictate how much needed when to estimate B Adaptive designs may be driven by formal utility functions u(R, B) or other explicit considerations of total evidence Substantial evidence of B>R for approval

Total Evidence can be generated via Adaptive Designs Generally acceptable for early “learning” phase development programs in Phase 1 and 2 Discouraged in confirmatory Phase 3 setting unless –exceptional circumstances (e.g. rare disease, special populations) –Additional (redundant?) fixed design studies dominate the confirmatory development plan

Clinical Development Planning with Regulators Meaning of any claims or conclusions made Target Product Profile (TPP) Relationship between claims and evidence Clinical development plan from “first in man” to approval Study protocols and simulations supporting error rate control Data Monitoring Committee charters, information control, and sponsor decision-making plan, statistical analysis plans Quality of the evidence Locked database documentation DMC reports, information control results Totality of the evidence (e.g. “substantial”) Study reports/synopses, integrated summaries, etc.

Timing for Regulatory Communication Communicate when you have the evidence needed to support your plans –As early as possible (e.g. Pre IND meetings or written feedback) –How much / how detailed depends on stage of development –If you want definitive regulatory action then provide fairly definitive proposals

New Regulatory Horizons Exploratory INDs End of Phase 2A meetings Large, “simple”, “outcome” studies –Pre-approval Risk Management Cardiovascular assessment of anti-diabetes drugs –FDA Amendments Act of 2007 Risk Evaluation and Mitigation Strategy (REMS) –Observational –Comparative effectiveness

Regulator’s Perspective Pro’s –Risk and benefit information can drive safe dose selection, patient populations to study, etc. –Stratified medicine via appropriately targeted labeling Con’s –Summary test statistics and other inferential tools depend on a less certain and more complicated sample space –Chance of wrong decisions goes up –Longer, more intensive reviews needed

Time to Act is Now Sponsors can develop adaptive design proposals that align with the regulator’s review lens at appropriate stages of drug development Window of opportunity – don’t be shy about proposing adaptive designs. Success in early phase development will support enhanced use in confirmatory phase development.